Fig. 4

Potential targeted therapies for A-to-I RNA editing in cancer and tumour immunotherapy: A Site-directed RNA editing by harnessing ADARs; B Nuclear export inhibitors (NEIs) such as KPT-330 sequester ADAR1p150 in the nucleus; C Anti-cancer epigenetic inhibitors induce transcription of repetitive sequences that form dsRNAs and continuously activate the dsRNA sensor pathway; D Z-DNA inducer CBL0137 induces the formation of Z-DNA and activates ZBP1